ArticleJournal of substance abuse treatment2011
Advancing performance measures for use of medications in substance abuse treatment.
Article in Journal of substance abuse treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care.Journal of substance abuse treatment · 2015Trial
- The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Journal of studies on alcohol and drugs · 2014Trial
- Characterizing intersystem and community values to enhance opioid use disorder treatments: Communities That Heal intervention in New York.The International journal on drug policy · 2025Article
- Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.Journal of substance abuse treatment · 2020Article
- Developing an opioid use disorder treatment cascade: A review of quality measures.Journal of substance abuse treatment · 2018Review
- Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.Addiction science & clinical practice · 2013Article
- Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.Journal of substance abuse treatment · 2013Article
- Financial factors and the implementation of medications for treating opioid use disorders.Journal of addiction medicine · 2012Article
- Performance measures for substance use disorders--what research is needed?Addiction science & clinical practice · 2012Article
- Article
- Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.Psychiatric services (Washington, D.C.) · 2012Article
- A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.Journal of substance abuse treatment · 2011Article
- A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.Journal of studies on alcohol and drugs · 2011Article
- Specifying and Pilot Testing Quality Measures for the American Society of Addiction Medicine's Standards of Care.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Performance measures have the potential to drive high-quality health care. However, technical and policy challenges exist in developing and implementing measures to assess substance use disorder (SUD) pharmacotherapy. Of critical importance in advancing performance measures for use of SUD pharmacotherapy is the recognition that different measurement approaches may be needed in the public and private sectors and will be determined by the availability of different data collection and monitoring systems. In 2009, the Washington Circle convened a panel of nationally recognized insurers, purchasers, providers, policy makers, and researchers to address this topic. The charge of the panel was to identify opportunities and challenges in advancing use of SUD pharmacotherapy performance measures across a range of systems. This article summarizes those findings by identifying a number of critical themes related to advancing SUD pharmacotherapy performance measures, highlighting examples from the field, and recommending actions for policy makers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.